The latest edition of the New England Journal of Medicine features three new studies about a drug that has been withdrawn from the market. Publication comes days before the Food and Drug Administration is scheduled to start hearings on whether to allow sales of Tysabri, which was used to treat people with multiple sclerosis.
The Cambridge-based company, Biogen Idec, withdrew its drug from the market last year after two patients developed a lethal brain disease.
Health and science reporter Allan Coukell has more on the story.
This program aired on March 2, 2006. The audio for this program is not available.